TTC19

Across TCGA pan-cancer cohorts, TTC19 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC19 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TTC19 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TTC19 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where TTC19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	1.000	0.768	.003	34	view →
HNSC	OS	Tertile	All	0.589	0.841	.006	23	view →
UCEC	OS	Median	II,III,IV	1.000	0.653	.020	4	view →
PDAC	OS	Tertile	All	0.387	0.602	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTC19–CCRCC (OS)

Open the CCRCC breakdown →